Top 10 Lung Cancer Trials to Watch at ASCO 2026
ASCO 2026 should bring a dense run of lung cancer updates, and a handful of studies stand out because they could shape frontline treatment decisions, refine biomarker-specific standards, or push targeted therapy further into earlier-stage disease. Some of these are classic stock-moving readouts tied to a single asset. Others matter more because they can shift the field's treatment logic even if the immediate market reaction is smaller.